Scholar Rock (SRRK) Competitors $32.40 +0.50 (+1.57%) Closing price 04:00 PM EasternExtended Trading$32.39 -0.01 (-0.03%) As of 06:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SRRK vs. ASND, VTRS, RDY, MRNA, ROIV, QGEN, ELAN, BBIO, VRNA, and RVMDShould you be buying Scholar Rock stock or one of its competitors? The main competitors of Scholar Rock include Ascendis Pharma A/S (ASND), Viatris (VTRS), Dr. Reddy's Laboratories (RDY), Moderna (MRNA), Roivant Sciences (ROIV), QIAGEN (QGEN), Elanco Animal Health (ELAN), BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), and Revolution Medicines (RVMD). These companies are all part of the "pharmaceutical products" industry. Scholar Rock vs. Its Competitors Ascendis Pharma A/S Viatris Dr. Reddy's Laboratories Moderna Roivant Sciences QIAGEN Elanco Animal Health BridgeBio Pharma Verona Pharma PLC American Depositary Share Revolution Medicines Ascendis Pharma A/S (NASDAQ:ASND) and Scholar Rock (NASDAQ:SRRK) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, valuation, earnings, dividends and media sentiment. Which has better earnings and valuation, ASND or SRRK? Scholar Rock has lower revenue, but higher earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Scholar Rock, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAscendis Pharma A/S$393.54M32.47-$409.12M-$5.16-40.14Scholar Rock$33.19M93.84-$246.29M-$2.91-11.13 Is ASND or SRRK more profitable? Scholar Rock has a net margin of 0.00% compared to Ascendis Pharma A/S's net margin of -54.94%. Ascendis Pharma A/S's return on equity of 0.00% beat Scholar Rock's return on equity.Company Net Margins Return on Equity Return on Assets Ascendis Pharma A/S-54.94% N/A -24.31% Scholar Rock N/A -127.11%-90.09% Do insiders & institutionals believe in ASND or SRRK? 91.1% of Scholar Rock shares are owned by institutional investors. 40.0% of Ascendis Pharma A/S shares are owned by insiders. Comparatively, 13.3% of Scholar Rock shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has more volatility and risk, ASND or SRRK? Ascendis Pharma A/S has a beta of 0.41, meaning that its share price is 59% less volatile than the S&P 500. Comparatively, Scholar Rock has a beta of 0.42, meaning that its share price is 58% less volatile than the S&P 500. Does the media prefer ASND or SRRK? In the previous week, Scholar Rock had 8 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 21 mentions for Scholar Rock and 13 mentions for Ascendis Pharma A/S. Scholar Rock's average media sentiment score of 0.82 beat Ascendis Pharma A/S's score of 0.65 indicating that Scholar Rock is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Scholar Rock 6 Very Positive mention(s) 5 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend ASND or SRRK? Ascendis Pharma A/S presently has a consensus price target of $248.29, indicating a potential upside of 19.88%. Scholar Rock has a consensus price target of $48.60, indicating a potential upside of 50.00%. Given Scholar Rock's stronger consensus rating and higher possible upside, analysts clearly believe Scholar Rock is more favorable than Ascendis Pharma A/S.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ascendis Pharma A/S 1 Sell rating(s) 0 Hold rating(s) 15 Buy rating(s) 0 Strong Buy rating(s) 2.88Scholar Rock 1 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 3 Strong Buy rating(s) 3.07 SummaryScholar Rock beats Ascendis Pharma A/S on 12 of the 17 factors compared between the two stocks. Get Scholar Rock News Delivered to You Automatically Sign up to receive the latest news and ratings for SRRK and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SRRK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SRRK vs. The Competition Export to ExcelMetricScholar RockMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.11B$3.40B$6.05B$10.51BDividend YieldN/A2.30%5.73%4.80%P/E Ratio-11.1322.9285.4427.36Price / Sales93.84268.92516.11196.40Price / CashN/A46.9537.5761.53Price / Book8.2210.5512.426.82Net Income-$246.29M-$52.58M$3.32B$276.89M7 Day Performance-16.26%1.09%1.01%0.27%1 Month Performance-3.77%16.09%10.75%8.31%1 Year Performance13.52%18.41%76.19%35.60% Scholar Rock Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SRRKScholar Rock4.6845 of 5 stars$32.40+1.6%$48.60+50.0%+11.9%$3.11B$33.19M-11.13140Options VolumeHigh Trading VolumeASNDAscendis Pharma A/S3.1962 of 5 stars$210.83+3.3%$244.36+15.9%+62.5%$12.59B$393.54M-40.861,017News CoverageAnalyst ForecastAnalyst RevisionHigh Trading VolumeVTRSViatris2.3836 of 5 stars$10.13-0.6%$10.40+2.7%-12.8%$11.88B$14.74B-3.4932,000News CoverageAnalyst ForecastRDYDr. Reddy's Laboratories2.7137 of 5 stars$14.12-0.3%$16.95+20.0%-11.6%$11.82B$3.81B21.3927,811News CoveragePositive NewsMRNAModerna4.26 of 5 stars$27.54-3.3%$41.81+51.8%-54.5%$11.08B$3.24B-3.665,800ROIVRoivant Sciences3.063 of 5 stars$16.26+0.6%$19.94+22.6%+38.5%$11.04B$29.05M-23.23860Insider TradeQGENQIAGEN4.3804 of 5 stars$46.99+0.4%$49.40+5.1%+10.8%$10.40B$1.98B27.765,765ELANElanco Animal Health2.78 of 5 stars$20.68+0.2%$18.33-11.3%+41.0%$10.25B$4.44B24.059,000Analyst RevisionBBIOBridgeBio Pharma4.1045 of 5 stars$54.61+3.3%$63.94+17.1%+119.2%$10.11B$221.90M-13.35400VRNAVerona Pharma PLC American Depositary Share1.4594 of 5 stars$106.91+0.1%$109.00+2.0%N/A$9.20B$42.28M-107.9930Positive NewsRVMDRevolution Medicines4.1135 of 5 stars$46.58-0.3%$74.64+60.2%-3.5%$8.73B$11.58M-10.35250 Related Companies and Tools Related Companies ASND Competitors VTRS Competitors RDY Competitors MRNA Competitors ROIV Competitors QGEN Competitors ELAN Competitors BBIO Competitors VRNA Competitors RVMD Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SRRK) was last updated on 10/15/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Scholar Rock Holding Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Scholar Rock With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.